Failure To Launch: Pravachol, Zocor And The Future Of 180-Day Exclusivity
Executive Summary
Some of the most anticipated generic launches in recent years will be more limited than originally projected following court decisions creating 180-day exclusivity periods for generics of Bristol-Myers Squibb's Pravachol and Merck's Zocor
You may also be interested in...
Generic Mobic, Celexa Launches Are Not Indicative Of Price Erosion – Teva
The deep discounts seen with some recent high profile generic launches are not reflective of an eroding generic pricing environment, Teva maintains
Generic Mobic, Celexa Launches Are Not Indicative Of Price Erosion – Teva
The deep discounts seen with some recent high profile generic launches are not reflective of an eroding generic pricing environment, Teva maintains
AstraZeneca Rides Wave Of Crestor Data; Is Pfizer Facing Lipitor Wipeout?
Wall Street appears to feel that AstraZeneca has weathered the run up to the launch of generic statins far better than Pfizer